Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer

Clinical Chemistry

Volumn 53, Issue 7, 2007, Pages 1280-1288

  Sieuwerts, Anieta M ^a,c   Usher, Pernille A ^b   Meijer Van Gelder, Marion E ^a   Timmermans, Mieke ^a   Martens, John W M ^a   Brünner, Nils ^b   Klijn, Jan G M ^a   Offenberg, Hanne ^b   Foekens, John A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL PROTOCOL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; PROTEIN ANALYSIS; RNA SPLICING; TUMOR CELL;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; EXONS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; RNA SPLICING; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 34347375084     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.082800     Document Type: Article

References (24)

1. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997;3:1623-8.
2. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999;84:44-8.
3. Castello R, Estelles A, Vazquez C, Falco C, Espana F, Almenar SM, et al. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. Clin Chem 2002;48:1288-95.
4. Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002;197:307-13.
5. Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2003;2:164-72.
6. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004;10:2289-98.
7. Kuvaja P, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma. Oncology 2005;68:196-203.
8. Nakopoulou L, Giannopoulou I, Lazaris A, Alexandrou P, Tsirmpa I, Markaki S, et al. The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. Apmis 2003;111:1027-36.
9. Inoue H, Mimori K, Shiraishi T, Kataoka A, Sadanaga N, Ueo H, et al. Expression of tissue inhibitor of matrix metalloproteinase-1 in human breast carcinoma. Oncol Rep 2000;7:871-4.
10. Span PN, Lindberg RL, Manders P, Tjan-Heijnen VC, Heuvel JJ, Beex LV, et al. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol 2004;202:395-402.
11. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-52.
12. Wurtz SO, Schrohl AS, Sorensen NM, Lademann U, Christensen IJ, Mouridsen H, et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 2005;12:215-27.
13. Luparello C, Avanzato G, Carella C, Pucci-Minafra I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999;54:235-44.
14. Porter JF, Shen S, Denhardt DT. Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase. Br J Cancer 2004;90:463-70.
15. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999;59:6267-75.
16. Lee SJ, Yoo HJ, Bae YS, Kim HJ, Lee ST. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem Biophys Res Commun 2003;312:1196-201.
17. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005;65:898-906.
18. Tomlinson J, Barsky SH, Nelson S, Singer S, Pezeshki B, Lee MC, et al. Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 1999;5:3516-22.
19. Wurtz SO, Christensen IJ, Schrohl AS, Mouridsen H, Lademann U, Jensen V, et al. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients. Mol Cell Proteomics 2005;4:483-91.
20. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. Lancet 2005;365:671-9.
21. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, et al. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 2005;11:7311-21.
22. Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, et al. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 2006;12:3319-28.
23. Holten-Andersen MN, Hansen U, Brunner N, Nielsen HJ, Illemann M, Nielsen BS. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer 2005;113:198-206.
24. Martens JW, Sieuwerts AM, Bolt-deVries J, Bosma PT, Swiggers SJ, Klijn JG, et al. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thromb Haemost 2003;89:393-404.